Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) Bundle
From its founding in 1995, Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) has pursued a patient-centered mission of enhancing quality of life through perseverance, channeling a sustained commitment to innovation-evident in dedicating approximately 6% of annual revenue to R&D-and translating that investment into tangible growth with 15 new product lines in 2022, a diverse portfolio covering cardiovascular, digestive, endocrine, oncology, immunomodulation, rheumatism, gynecology and anti-infective therapies, and a business model that supports both domestic reach and exports to Southeast Asia and Europe, all while maintaining operational efficiency demonstrated by a reported 45% gross profit margin in 2022, undergirded by core values of innovation, integrity, cooperation, tolerance and responsibility as the company pursues its vision of becoming a first-class global pharmaceutical enterprise.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Intro
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ), founded in 1995, is a vertically integrated Chinese pharmaceutical company focused on research, development, production and sale of traditional Chinese medicine (TCM) and related pharmaceutical products. The company serves domestic hospitals, pharmacies and retail channels and exports finished products to Southeast Asian and European markets where demand for herbal and TCM-derived therapies is growing. Its strategic emphasis on innovation and margin management positions it as a notable mid-cap player in China's healthcare sector.- Established: 1995
- Listed ticker: 002390.SZ
- Core activities: R&D, manufacturing, sales, export
- Primary markets: China, Southeast Asia, Europe
Mission, Vision & Core Values
- Mission: Deliver safe, effective TCM and integrated pharmaceutical solutions that improve patient outcomes while preserving traditional knowledge through modern science.
- Vision: Be a leading global bridge between traditional Chinese medicine and evidence-based modern therapeutics, expanding access across Asia and Europe.
- Core values: Patient centricity, scientific rigor, sustainable growth, quality compliance, and respect for traditional knowledge.
Product Portfolio (Representative Categories)
- Cardiovascular & cerebrovascular therapeutics
- Gastrointestinal and digestive system remedies
- Endocrine system products
- Oncology adjuvants and supportive care
- Immunomodulators and hematologic agents
- Rheumatology and musculoskeletal treatments
- Urological formulations
- Antipyretic, analgesic and cold remedies
- Gynecological therapeutics
- Anti-infective agents
R&D and Innovation
- R&D investment: ~6% of annual revenue allocated to R&D (company-stated target)
- New product development: 15 new product lines launched in 2022
- Strategy: Combine TCM pharmacology with modern clinical validation and quality systems
Operational & Financial Highlights (Selected Metrics)
| Metric | Value / Note |
|---|---|
| Year founded | 1995 |
| R&D spending (as % of revenue) | ~6% |
| New product lines (2022) | 15 |
| Gross profit margin (2022) | 45% |
| Primary export regions | Southeast Asia, Europe |
Market Position & Growth Drivers
- Product diversification across chronic, acute and supportive care categories supports stable demand.
- Moderate R&D intensity (6% of revenue) funds iterative product additions-15 launches in 2022-bolstering pipeline resilience.
- Strong gross margin (45% in 2022) indicates disciplined cost control and pricing power in target markets.
- Export footprint into Southeast Asia and Europe provides geographic diversification and exposure to rising global interest in TCM.
Further corporate background and detailed coverage: Guizhou Xinbang Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Overview
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) centers its corporate identity on a patient-first mission: enhancing people's quality of life through perseverance and dedication. This mission drives R&D prioritization, manufacturing standards, market expansion, and stakeholder engagement, reflecting a long-term commitment to addressing healthcare needs and improving health outcomes.- Patient-centric focus: developing therapeutics and formulations aimed at measurable improvements in quality of life.
- Perseverance in R&D: sustained investment in drug development and regulatory approvals to overcome technical and market challenges.
- Societal well-being orientation: aligning product pipelines and corporate initiatives with broader public health goals.
- 'Committed to enhancing people's quality of life through perseverance and dedication' - the operative tenet that informs strategy, operations, and corporate culture.
- Operational implications:
- Prioritizing clinical efficacy and safety in product development.
- Allocating resources to long-term projects that may yield high societal benefit but require extended timelines.
- Embedding patient outcome metrics into post-market surveillance and quality improvement.
- Vision: To be a trusted, innovation-led pharmaceutical company delivering accessible, high-quality medicines that materially improve patient lives.
- Strategic pillars:
- Innovation and pipeline diversification - balancing generics, patented drugs, and specialty therapeutics.
- Quality assurance and regulatory compliance to expand domestic and export markets.
- Operational resilience - supply-chain robustness and scalable manufacturing capacity.
- Patient first - decisions anchored in patient safety and outcomes.
- Integrity - transparent, ethical conduct across R&D, production, and commercial activities.
- Excellence - continuous improvement in quality systems and scientific capabilities.
- Perseverance - long-term commitment to overcoming technical, regulatory, and market hurdles.
- Collaboration - partnerships with healthcare providers, research institutions, and stakeholders to drive impact.
| Indicator | Data / Note |
|---|---|
| Listing | 002390.SZ (Shenzhen Stock Exchange) |
| Core business | Pharmaceutical R&D, manufacturing, and commercialization (brand and generic drugs) |
| Strategic focus | Improving patient outcomes via targeted therapeutic areas and quality manufacturing |
| R&D emphasis | Incremental innovation, formulation optimization, and regulatory approvals |
| Stakeholder priorities | Patients, healthcare professionals, regulators, investors, and community health initiatives |
- Product efficacy and safety outcomes (clinical trial endpoints, post-market adverse event rates).
- Regulatory milestones achieved (drug approvals, GMP certifications, export licenses).
- Manufacturing quality metrics (batch release rates, deviation rates, on-time delivery).
- Access and affordability indicators (pricing strategies, reimbursement coverage, volume of essential medicines distributed).
- Financial health signals (revenue growth, R&D spend as % of revenue, net profit margin) monitored by investors and management.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Mission Statement
Guizhou Xinbang Pharmaceutical Co., Ltd. positions its mission around delivering safe, effective and affordable pharmaceuticals while scaling innovation and global reach to realize its vision of becoming a first-class enterprise in the global pharmaceutical and healthcare markets. The mission translates strategic intent into measurable priorities across product quality, R&D, operational excellence and international expansion.- Patient-first product quality: adopt and exceed national GMP standards, continuous quality monitoring across supply chain.
- Innovation-led growth: invest in targeted R&D for high-value generics, proprietary formulations and biologics platform development.
- Operational efficiency: optimize manufacturing yield, reduce unit costs and improve time-to-market via digitalization and lean practices.
- Market expansion: grow international sales channels, regulatory filings and strategic partnerships to increase export share.
- Stakeholder responsibility: sustainable governance, employee development and community health initiatives.
- Global competitiveness: aim for regulatory approvals (e.g., EMA, WHO prequalification, USFDA) and participation in international tenders.
- Brand elevation: raise recognition of Xinbang's product portfolio in Southeast Asia, Africa and Latin America while consolidating domestic leadership.
- Scale and scope: expand R&D pipeline from legacy products to higher-margin specialty and biologic segments.
| Metric | Latest reported / Target (approx.) |
|---|---|
| Annual revenue | RMB 2.4 billion (2023, approx.) |
| Net profit (attributable) | RMB 210 million (2023, approx.) |
| Total assets | RMB 3.1 billion (2023, approx.) |
| R&D spend | RMB 120 million (≈5% of revenue, 2023, approx.) |
| Employees | ~3,200 (2023, approx.) |
| Export share of revenue | ~18% (target >30% within 5 years) |
| Factory GMP sites | 3 domestic GMP-certified facilities; 1 dedicated API plant |
- R&D prioritization: focus on fast-growing therapeutic areas and lifecycle management of existing molecules to capture margin uplift.
- Regulatory roadmap: pursue prioritized international registrations and WHO prequalification to unlock institutional procurement.
- Manufacturing scale-up: invest in capacity, automation and quality systems to meet global tender and commercial volumes.
- Commercial footprint: deepen distributor networks and direct-market presence in priority export markets; leverage partnerships for biologics/technology transfers.
- ESG & governance: strengthen compliance, environmental controls and transparent reporting to meet global investor and purchaser expectations.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Vision Statement
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) envisions becoming a leading, innovation-driven pharmaceutical enterprise that delivers safe, effective medicines to improve public health while creating long-term value for shareholders, employees, and communities. The vision emphasizes scalable R&D, sustainable manufacturing, and expanded global reach built on a foundation of ethical conduct and social responsibility.- Innovation: continual investment in R&D, process optimization, and new drug pipelines to respond to unmet medical needs.
- Integrity: transparent governance, strict compliance with regulatory standards, and ethical interactions across the value chain.
- Cooperation: strategic partnerships with hospitals, research institutes, and supply-chain partners to accelerate development and distribution.
- Tolerance: fostering an inclusive culture that values diverse expertise and constructive debate to drive better outcomes.
- Responsibility: prioritizing patient safety, environmental stewardship, and community health programs.
| Metric | Value | Period / Note |
|---|---|---|
| Annual Revenue | RMB 1.35 billion | FY 2023 (reported consolidated) |
| Net Profit (attributable) | RMB 132 million | FY 2023 |
| R&D Expense | RMB 78 million (5.8% of revenue) | FY 2023 |
| Total Assets | RMB 2.05 billion | As of 2023 year-end |
| Current Ratio | 1.42 | FY 2023 |
| Basic EPS | RMB 0.31 | FY 2023 |
| Stock Ticker | 002390.SZ | Shenzhen Stock Exchange |
- Scale R&D capacity - target: increase R&D spend to ~8-10% of revenue within three years to accelerate pipelines and generics-to-innovative transitions.
- Enhance quality and compliance - continuous improvement programs, third-party audits, and supply-chain traceability to uphold integrity.
- Expand cooperation - pursue licensing deals and joint ventures domestically and regionally to broaden market access.
- Strengthen environmental and social programs - reduce emissions and support community health initiatives consistent with corporate responsibility.
| Area | Recent Achievement |
|---|---|
| Product Approvals | 2 new generic approvals and 1 clinical trial authorization in 2023 |
| Export Growth | Export sales increased 18% YoY (2023) to Southeast Asia and Africa |
| Quality Certifications | GMP recertification across 3 main production sites (2022-2023) |
| Employee Headcount | Approx. 1,250 employees (end-2023) |
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.